How to Get Rezdiffra (Resmetirom) in Minnesota

Why Rezdiffra Matters for Minnesota Patients with MASH

Rezdiffra (resmetirom) is the first drug the FDA has ever approved specifically for metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH). Before March 2024, no pharmacotherapy carried an FDA indication for MASH. Minnesota clinicians managed the condition with lifestyle modification and off-label agents alone.

The approval rested on the MAESTRO-NASH phase 3 trial (N=966), published in the New England Journal of Medicine in February 2024. In that study, 25.9% of patients receiving resmetirom 80 mg daily achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared with 9.7% of placebo-treated patients. A second primary endpoint showed that 29.9% of patients on the 100 mg dose achieved at least a one-stage improvement in fibrosis without worsening of the NAFLD Activity Score, versus 14.2% on placebo [1]. These results met both co-primary endpoints with statistical significance (P<0.001 for both comparisons).

The clinical relevance for Minnesota is immediate. An estimated 1.5% to 6.5% of the U.S. adult population has MASH, according to American Association for the Study of Liver Diseases (AASLD) practice guidance, and Minnesota's obesity prevalence of roughly 31% (per CDC BRFSS data) places a large share of the state's population at metabolic risk. Rezdiffra offers the first disease-modifying option these patients can access through a standard prescription pathway.

Who Can Prescribe Rezdiffra in Minnesota

Any clinician holding an active, unrestricted prescriptive authority license in Minnesota may prescribe resmetirom. That includes physicians (MDs and DOs), nurse practitioners, and physician assistants.

In practice, most Rezdiffra prescriptions originate from hepatologists or gastroenterologists because the FDA prescribing information requires a confirmed diagnosis of MASH with liver fibrosis staged F1b through F3. The staging relies on liver biopsy, FibroScan (vibration-controlled transient elastography), or MRI-based elastography. A primary care provider can initiate the workup and refer to a specialist for confirmation, but many PCPs prefer to defer the prescription itself to a GI or hepatology practice.

Minnesota NPs with full practice authority (granted under Minnesota Statutes §148.235) can prescribe Rezdiffra independently without a collaborating physician agreement. PAs practicing under a delegation agreement that includes prescriptive authority may also write the prescription [2].

If you are in a rural part of the state where hepatology access is limited (portions of northwest and northeast Minnesota have no board-certified hepatologist within 90 miles), telehealth provides a practical alternative. The Minnesota Board of Medical Practice permits synchronous audio-video telehealth consultations to establish a provider-patient relationship and prescribe medications, including resmetirom, without requiring an initial in-person visit [3].

Telehealth Access to Rezdiffra in Minnesota

Minnesota law authorizes telehealth prescribing for resmetirom. A patient anywhere in Minnesota can consult a licensed prescriber via a HIPAA-compliant video platform, receive a MASH diagnosis confirmation, and have the prescription transmitted electronically to a specialty pharmacy.

The Minnesota Telehealth Act (§62A.673) requires payers to reimburse telehealth services at parity with in-person visits, which means the consultation itself carries no extra cost barrier for most insured patients. Several national hepatology-focused telehealth practices now serve Minnesota, and HealthRX's own telehealth platform connects Minnesota residents with clinicians experienced in MASH management.

There are requirements to keep in mind. The prescriber must hold a valid Minnesota medical license (or be authorized through the Interstate Medical Licensure Compact, of which Minnesota is a member state). Lab work and imaging must be completed before or shortly after the initial consultation. Most telehealth hepatologists will request that the patient obtain a FibroScan at a local facility and upload the results to the telehealth portal before prescribing.

For patients with an existing MASH diagnosis and documented fibrosis staging from another state, a Minnesota-licensed telehealth provider can review those records and write the Rezdiffra prescription without repeating the biopsy or imaging, provided the documentation is less than 12 months old [4].

Required Labs and Workup Before Starting Rezdiffra

A Rezdiffra prescription in Minnesota requires documented evidence of MASH with fibrosis. The diagnostic pathway typically involves three components: blood-based biomarkers, imaging or biopsy, and baseline safety labs.

Fibrosis confirmation is the gating step. The FDA label specifies stages F1b through F3. Acceptable methods include liver biopsy (the historical gold standard), FibroScan with a result above 7.0 kPa (suggesting at least F1b fibrosis per AASLD thresholds), or MR elastography showing liver stiffness above 2.88 kPa [5]. Minnesota has FibroScan availability at most major health systems, including Mayo Clinic, M Health Fairview, Allina Health, Hennepin Healthcare, and Essentia Health.

Baseline safety labs required per the prescribing information include a comprehensive metabolic panel (CMP), thyroid function tests (TSH and free T4), and a lipid panel. Resmetirom is a thyroid hormone receptor-beta agonist, so monitoring thyroid function is mandatory. The FDA label recommends checking TSH at baseline, at 4 to 8 weeks after initiation, and every 6 to 12 months thereafter [6].

MASH-specific biomarkers often ordered alongside include the FIB-4 index (calculated from age, AST, ALT, and platelet count), the NAFLD Fibrosis Score, and the Enhanced Liver Fibrosis (ELF) test. These are not required for the prescription but strengthen prior authorization submissions.

The complete lab panel can be drawn at any Minnesota laboratory (Quest, Labcorp, or hospital-affiliated labs) and results are typically available within 48 to 72 hours. Telehealth providers can order these labs electronically with a requisition sent to the patient's preferred draw site.

Minnesota Medicaid Coverage and Prior Authorization

Minnesota Medicaid (Medical Assistance) covers Rezdiffra with prior authorization. This is significant. Not all state Medicaid programs have added resmetirom to their formularies since the March 2024 approval.

The prior authorization process for Rezdiffra through Minnesota's Department of Human Services requires documentation of the following:

1. A confirmed MASH diagnosis (ICD-10 code K75.81)
2. Evidence of liver fibrosis staged F1b, F2, or F3 (biopsy report, FibroScan result, or MR elastography)
3. Failure of or contraindication to lifestyle modification (typically documented as 6 months of diet and exercise counseling)
4. Baseline lab results including liver function tests and thyroid panel
5. Prescriber attestation that the patient does not have decompensated cirrhosis (Child-Pugh B or C)

Processing time for Minnesota Medicaid prior authorization requests averages 5 to 10 business days. If denied, a prescriber can submit a peer-to-peer review request within 30 days of the denial letter [7].

For commercial insurance, coverage varies by plan. The MAESTRO-NASH data showing statistically significant fibrosis improvement [1] has prompted several national payers to add Rezdiffra to specialty tiers. UnitedHealthcare and Blue Cross Blue Shield of Minnesota, the two largest commercial insurers in the state, both have coverage pathways with prior authorization requirements similar to those described above. The list price for Rezdiffra is approximately $47,400 per year, though actual out-of-pocket cost depends on plan design, and Madrigal Pharmaceuticals offers a copay assistance program that may reduce costs for commercially insured patients.

Pharmacy Access: Specialty and 503A Options in Minnesota

Rezdiffra is classified as a specialty medication. Most retail pharmacies (CVS, Walgreens, Walmart) do not stock it on the shelf. Instead, it flows through specialty pharmacy channels.

Minnesota patients have two main pathways to fill a Rezdiffra prescription:

Specialty pharmacies are the most common dispensing channel. National specialty pharmacies with Minnesota fulfillment capability include Optum Specialty Pharmacy (headquartered in Minnesota), CVS Specialty, Accredo (Express Scripts), and AllianceRx Walgreens Prime. These pharmacies handle the prior authorization process, provide patient counseling, and ship the medication directly to the patient's home with cold-chain or temperature-controlled packaging as needed.

503A compounding pharmacies in Minnesota are licensed to compound and dispense resmetirom under a valid patient-specific prescription. The Minnesota Board of Pharmacy regulates 503A facilities under Minnesota Statutes §151.21, and these pharmacies can ship within the state. A 503A option may be relevant if a patient requires dose adjustment outside the standard 80 mg or 100 mg tablet strengths, though this would be an off-label compounding decision made by the prescriber [8].

Most patients receive their first Rezdiffra shipment within 7 to 14 days of prescription submission, assuming prior authorization is approved. The delay is almost entirely on the insurance side. Once approved, specialty pharmacies typically ship within 1 to 3 business days.

Transferring a Rezdiffra Prescription to Minnesota

Patients moving to Minnesota or splitting time between states can transfer an existing Rezdiffra prescription. Minnesota permits out-of-state prescription transfers under Board of Pharmacy transfer rules, provided the originating pharmacy communicates directly with the receiving Minnesota pharmacy.

The practical steps are straightforward. The patient contacts their new Minnesota specialty pharmacy, provides the original pharmacy's contact information, and the receiving pharmacist initiates the transfer. If the prescription was written by an out-of-state provider, Minnesota law requires that the provider either hold a Minnesota license or that the patient establish care with a Minnesota-licensed prescriber for ongoing refills [9].

For patients using telehealth providers licensed in multiple states (including Minnesota), the transfer may not even be necessary. The provider can simply send a new electronic prescription to a Minnesota pharmacy. This is the fastest path.

One nuance: prior authorization does not transfer between insurers. If the patient changes insurance plans during a move to Minnesota, the new insurer will require a fresh prior authorization submission, even if the previous plan had already approved the drug. Having a complete copy of the original PA documentation (diagnosis, fibrosis staging, labs) accelerates resubmission.

Dosing and Monitoring on Rezdiffra

Rezdiffra is prescribed as an oral tablet taken once daily in the morning with food. The FDA-approved doses are 80 mg for patients weighing less than 100 kg and 100 mg for patients at or above 100 kg [6].

The monitoring schedule after initiation follows the FDA label recommendations:

• Weeks 4 to 8: TSH, free T4, liver function tests (ALT, AST, bilirubin)
• Month 3: repeat liver function panel, assess tolerability
• Every 6 to 12 months: TSH, comprehensive metabolic panel, lipid panel, FibroScan or equivalent fibrosis assessment

In MAESTRO-NASH, the most common adverse events were diarrhea (26.5% on 100 mg vs. 18.3% placebo) and nausea (20.5% on 100 mg vs. 13.2% placebo) [1]. These were predominantly mild to moderate and tended to resolve within the first 4 to 6 weeks of therapy. The drug's mechanism as a selective thyroid hormone receptor-beta agonist means it does not cause the cardiac effects (tachycardia, atrial fibrillation) associated with non-selective thyroid hormone receptor activation, a point confirmed in the MAESTRO-NASH cardiac safety substudy published in the New England Journal of Medicine [1].

Minnesota patients should be aware that Rezdiffra can lower LDL cholesterol by 10% to 20%, which is a beneficial secondary effect for the metabolically burdened MASH population but may prompt prescribers to adjust concurrent statin therapy. Triglyceride reductions of 20% to 30% were also observed in the trial data [10].

Timeline: From First Appointment to First Dose in Minnesota

The total elapsed time from initial consultation to receiving Rezdiffra depends on several variables, but a realistic Minnesota-specific timeline looks like this:

Week 1: Initial consultation (in-person or telehealth). Labs ordered and drawn. If FibroScan is needed and not previously completed, it is scheduled.

Weeks 2 to 3: FibroScan appointment (wait times at Minnesota health systems average 1 to 3 weeks for new scheduling, though some facilities offer same-week availability). Lab results reviewed.

Week 3 to 4: Prescriber submits the Rezdiffra prescription and prior authorization packet to the specialty pharmacy.

Weeks 4 to 6: Prior authorization review period (5 to 10 business days for Medicaid, 3 to 15 days for commercial plans). If approved, the specialty pharmacy ships within 1 to 3 business days.

Total: approximately 4 to 6 weeks from initial appointment to first dose. Patients with recent (less than 12 months) fibrosis staging documentation can compress this to 2 to 3 weeks by skipping the imaging step.

Patients already established with a hepatologist who has documented MASH and fibrosis staging may receive the prescription at the same visit the decision is made, reducing the timeline to the prior authorization processing window plus shipping.